#96 - Pathology platforms, pumped-up funding rounds & pelagic collagen
The coffee break biotech roundup, by SomX.
Hello, my fellow seafarers,
This week has been anything but calm waters: Isomorphic Labs is going full steam ahead on one of the largest funding rounds in biotech history, Roche dropped a quarter‑billion dollar bounty on an AI pathology deal, a Bristol-based biotech is making waves toward a potential hantavirus vaccine, Kyverna is preparing to drop anchor with one of the first CAR-T therapies for autoimmune disease, and jellyfish are emerging as a surprisingly sustainable source of collagen.
Mind the tentacles!
Dodo
If you’d like to sponsor a future edition of Biotech Dodo, send us a message.
Treating a new realm of diseases
Beyond traditional limits: explore the drug delivery technology opening new doors in genomic medicine.
Discover 🔍
💰 AI-fuelled Isomorphic bags $2.1B, the second largest biotech round ever (BioSpace): Alphabet’s AI-driven biotech has hauled in one of the biggest biotech rounds in history, despite having no disclosed molecules and nothing in the clinic. In a market where investors are fleeing early-stage risk and piling into late-stage assets, Isomorphic is a rather peculiar outlier. Rather than focusing on one target, the company plans to build a broader pipeline, particularly across oncology and immunology.
Our take: Isomorphic is being valued as a multi-programme AI operating system for drug discovery, rather than a pipeline of discrete assets. It has to be said, traditional biotech models – where capital is tied to specific indications and milestones – look rather old-fashioned by comparison. Platform companies spawning dozens of programmes across partners will compress valuation multiples for single-asset peers. The bar for non-platform biotechs just got considerably higher.
🤑 Roche acquires PathAI for $750m upfront to advance AI-powered digital pathology (BioXconomy): Roche is taking its long-standing partnership with PathAI to a rather logical conclusion, hauling the AI pathology specialist in-house in a deal worth $750M, with up to $300M in milestones. The deal tucks PathAI neatly into Roche’s diagnostics division. At the heart of the deal is PathAI’s AI-powered Image Management System, designed to streamline lab workflows and deliver faster, more accurate diagnoses from digital tissue samples.
Our take: With this move, Roche is getting ahead of a scenario where a rival pharma or diagnostics giant secures a scalable computational pathology backbone first. AI-assisted pathology is becoming as routine as sequencing or imaging – whoever controls the underlying software stack gains outsized influence over how cancer trials are designed, how biomarkers are validated, and how “digital” pathology gets defined in everyday clinical practice.
💉 Bristol biotech firm makes strides in developing a vaccine for hantavirus (Bristol 24/7): EnsiliTech is developing an mRNA-LNP vaccine candidate for hantavirus, following the recent outbreak aboard the MV Hondius that claimed three lives. Backed by the Small Business Research Initiative, the University of Bath spinout has produced a candidate showing rather promising results in animal testing. The team is now seeking additional funding to continue preclinical development and move towards IND approval.
Our take: Hantavirus sits in a rather awkward spot commercially: it’s lethal enough to matter, but outbreaks are scattered across regions that don’t exactly scream high-margin markets. That leaves public funding and partnerships doing the heavy lifting, rather than classic pharma pull, with EnsiliTech’s progress contingent on whether enough institutions remain willing to bankroll neglected infectious-disease innovation as the headlines move on.
💊 Kyverna begins rolling submission for autoimmune CAR-T as FDA requests more natural history analysis (Fierce Pharma): Kyverna is inching toward a landmark FDA approval for miv-cel, which could become the first autoimmune CAR-T to reach the market. The company has filed a rolling Biologics License Application after winning FDA backing for the notion that its single-arm KYSA-8 trial can support an application for stiff person syndrome, alongside additional analysis from a 153-patient natural history study.
Our take: After the FDA rejected uniQure’s Huntington’s gene therapy on natural history grounds, the same playbook looked rather shakier for cell and gene therapies. Kyverna securing FDA alignment on that design suggests the agency hasn’t entirely closed the door. If the FDA approves, small, high-need autoimmune indications could become proving grounds for cell therapies that would otherwise struggle to launch in broader, messier patient populations.
And finally…
🪼 How jellyfish bycatch could be valuable collagen source for cosmetics and biotech (Frontiers): Marine scientists Dr Ainara Ballesteros and PhD student Raquel Torres are turning a rather slimy ocean nuisance into biotech feedstock. Jellyfish bycatch from small-scale Spanish fisheries can be transformed into rather impressive collagen – rivalling material from carefully collected specimens. Their work blends fieldwork alongside fishers with lab-bench science, showing that what’s routinely tipped overboard could become a sustainable source of marine collagen for cosmetics, biomedicine, and regenerative medicine.
Our take: Jellyfish bycatch has clear promise on paper as a collagen feedstock, but small-scale fleets lack the onboard kit to turn nuisance into commodity. Fleets will require dedicated handling, chilling, and sorting, which means investing in the entire value chain from deck to lab. Coastal institutions would also need to reconfigure their facilities to treat jellyfish as proper marine-biotech feedstock rather than waste.
Tune in 🎧
🧠 Acadia CEO Catherine Owen Adams on neurodegeneration, AI and building biotech vision: From UK pharmacist to biotech CEO, Catherine Owen Adams shares how storytelling shapes leadership across commercialisation, investor engagement, and enterprise vision.
🦠 Building a new antibody discovery platform with Infinimmune’s Wyatt McDonnell, PhD: Infinimmune’s CEO unpacks how single-cell biology and computation are reshaping antibody discovery – and how that approach landed them a Merck collaboration worth up to $838M.
🤖 AI and the future of healthcare: Dr. Emilia Javorsky explores AI’s realistic potential in cancer research and healthcare, examining the role of high-quality data, patient-level individualisation, and the systemic reforms needed to unlock meaningful impact.
Apply ✍️
🥼 Account Manager Pharma, bioMérieux: Interested in bridging science and commercial strategy? You’ll drive sales and marketing across the South of England, combining scientific expertise in advanced therapies with business acumen.
🤝 Meetings Centre of Excellence Manager, GSK: Passionate about high-impact HCP engagement? You’ll lead the UK strategy for healthcare professional meetings and external events, partnering cross-functionally to deliver compliant, customer-centric solutions.
RSVP 📆
🔬 19–21.05 | Bio-IT World Conference & Expo | Boston, USA: Twenty-five years in, Bio-IT World remains an event where biopharma, clinical research, and tech genuinely converge – and with this year's focus on informatics, data analytics, and AI-driven tools, the timing could hardly be better.
🧪 22–23.05 | PDA Applied Bioprocess Solutions Forum 2026 | Milan, Italy: This highly interactive, community-shaped forum focuses on the cross-industry bioprocessing challenges that don’t have easy answers – from development and manufacturing, to quality and regulatory compliance.
🧑⚕️ 01.06 | HealthTech Integrates 2026 | London, UK: This one‑day conference brings together HealthTech companies (technology, diagnostics, devices), clinicians, regulators and investors to wrestle with the gap between promising technology and real-world clinical practice.
Got news, jobs or events you think are worth coo-ing over? Post an event here, or email us at biotechdodo@substack.com!
We’re SomX – a communications and creative agency trusted by biotech, pharma and healthtech pioneers. We craft strategy, content, PR and design that translate complex biology into compelling stories and investor‑ready excitement. Get in touch to amplify your science beyond the lab bench.